Lymphoproliferation, chronic B cell activation resulting in hypergammaglobulinemia, and profound immunodeficiency are prominent features of a retrovirus-induced syndrome designated murine acquired immunodeficiency syndrome (MAIDS). In vivo treatment of infected mice with recombinant interleukin 12 (IL-12) beginning at the time of infection or up to 9 wk after virus inoculation markedly inhibited the development of splenomegaly and lymphadenopathy, as well as B cell activation and Ig secretion. Treatment with IL-12 also had major effects in preventing induction of several immune defects including impaired production of interferon 31 (IFN-~/) and IL-2 and depressed proliferative responses to various stimuli. The therapeutic effects of IL-12 on the immune system of mice with MAIDS were also associated with reduced expression of the retrovirus that causes this disease (BM5def), with lesser effects on expression of ecotropic MuLV. IL-12 treatment was not effective in IFN-y knockout mice or in infected mice treated simultaneously with IL-12 and anti-IFN-3,. These results demonstrate that induction and progression of MAIDS are antagonized by IL-12 through high-level expression of IFN-'y and may provide an experimental basis for developing treatments of retrovirus-induced immune disorders with similar immunopathogenic mechanisms.
M
urine AIDS (MAIDS) 1 develops in some strains of mice infected with the LP-BM5 mixture of murine leukemia viruses (MuLV) originally isolated by Laterjet an~ Duplan (1) . This mixture includes replication-competent, nonpathogenic helper viruses and etiologic replication-defective MuLV designated LP-BM5 def (2) or DuSH (3). MAIDS is characterized by an early, persistent polyclonal activation of CD4 + T cells accompanied by increasingly severe defects in cell-mediated immunity (4, 5) . Abnormalities of B cells are another prominent manifestation of the syndrome and include polyclonal activation associated with B cell proliferation and differentiation to Ig secretion resulting in hypergammaglobulinemia (5, 6) . As a consequence of B cell and CD4 + T lymphocyte proliferation, the susceptible strains of mice develop massive lymphadenopathy as well as splenomegaly and expression of these retroviruses increases progressively with time after infection (7, 8) .
1 Abbreviations used in this paper: HPRT, hypoxanthine phosphoribosyltransferase; MAIDS, murine AIDS; MuLV, murine leukemia virus; RT, reverse transcriptase. R. T. Gazzinelli and N. A. Giese contributed equally to this work. B lymphocytes are the major target for infection by LP-BM5 def (8) and their activation and expansion are essential components for the development of this disorder (9) . In MAIDS, B cell activation, and lymphoproliferation are dependent on CD4 + T cells (10, 11) and are associated with increased production of IL-4, IL-6, and IL-10 (Type 2 cytokines)2; and reduced expression of IL-2 and IFN-'y proteins (Type 1 cytokines) (12) . Type 2 cytokines efficiently stimulate B cell growth and differentiation to Ig secretion and may be of crucial importance to the chronic B cell activation and hypergammaglobulinemia, a central feature of this disease. High levels of such cytokines may also promote activation and replication of proviral DNA in B lymphocytes and therefore favor progression of MAIDS. Studies using IL-4-deficient mice suggest that there are strain-dependent differences in the importance of this particular Type 2 cytokine for devel-2 Studies identifying cells other than CD4 + T cells as important sources of IFN-'y (NK cells) or Ibl0 (B cells, macrophages), for example, suggest the use of the terms Type 1 and Type 2 to designate certain cytokine profiles rather than Thl and Th2 with their inherent implications of T cell origin. As many studies indicate that CD4+ T cells with Thl and Th2 features exist in vivo, Th subset terminology will still be used to refer to these cell types. opment of MAIDS. (B6 x 129)F2 mice with an IL-4 knockout had a much-delayed course of disease (13) , while progression of MAIDS was comparable in B6 knockout and wild-type mice (14) .
Nevertheless, Type 1 cytokines, through their ability to activate macrophages, cytotoxic T cells, and NK cells, may be important components in resistance to this retrovirus mixture. If Type 1 responses are protective to virus-infected mice, it would be expected that manipulations which enhance induction of Thl differentiation and Type I cytokine production would confer some measure of disease resistance to MAIDS-susceptible mice as manifested by reduced lymphoproliferation and improved cell-mediated immune function. We have explored this postulate by treating infected mice with IL-12.
IL-12 is a heterodimeric cytokine produced by macrophages in response to infection with various organisms. It acts in synergy with TNF-ot and IL-2 to induce the generation of IFN-3' by NK cells (15) (16) (17) (18) and acts on both CD8 + T and NK cells to enhance their cytotoxic activity (19) . Importantly, IL-12 also conditions naive helper cells to differentiate to the Thl pathway (20) (21) (22) and stimulates Th2 cells to transiently produce IFN-3' (23).
In the results presented here, we show that chronic treatment with rlL-12 for 4 wk, initiated at either 0 or 4 wk post infection, resulted in significantly reduced spleen and cervical lymph node weights and marked reductions in the severity of histopathologic changes and immune abnormalities associated with the progression of MAIDS. IL-12 treatment also had an inhibitory effect on expression of the retrovirus that causes the disease (BM5def) but had less of an effect on the replication-competent, nonpathogenic, ecotropic helper virus transcripts. Finally, our results show that the beneficial effects of IL-12 were dependent on IFN-3~ synthesis and were associated with inhibition of B cell proliferation and activation.
Materials and Methods
Mice and Viruses. 6-wk-old C57BL/6 (B6) female mice obtained from The Jackson Laboratory (Bar Harbor, ME) were injected intraperitoneally with 0.1 ml of stocks of LP-BM5 MuLV prepared as previously described (2) . IFN-3' knockout mice (24) used in our studies were obtained from Genentech Inc. (South San Francisco, CA), were backcrossed into B6 genetic background for five to six generations, and typed individually for the wild-type and defective IFN-'y genes. Frequencies of spleen cells producing infectious ecotropic MuLV were determined in infectious center tests using mitomycin C-treated cells (2, 7) .
1L,12 Treatment. ri1-12 (25) (5.6 x 106 U/mg) produced by the Mammalian and Microbial Cell Sciences and Process Biochemistry groups of Genetics Institute (Cambridge, MA; generously provided by Dr. Stan Wolf of that Institute) was diluted in PBS containing 0.1% BSA (PBS-BSA) and was inoculated intraperitoneally at 0.1-0.25/zg/mouse/d for 5 d, followed by 2 d with no inoculations. This cycle was repeated 4 or 8 times, with the first round starting at day 0 or day 1 after infection in protocols designed to test effects of II-12 on early disease. Mice were tested at 8-10 wk post infection. For protocols designed to test effects of ri1-12 on established disease, mice were infected for 4 or 8 wk before starting treatment with rlL-12 for four cycles. Some infected mice were treated simultaneously with I1-12 and anti-IFN--y mAb (XMG1.6) at a dose of 2 mg of partially purified (26) mAb/ mouse/wk. Normal mice, uninfected mice treated with rlIA2, and infected mice treated with PBS-BSA served as controls.
Studies of lnfected Mice. At autopsy, mice were bled, spleen and cervical lymph node (LN) weights were determined, and selected tissues were obtained for histopathologic studies. Single-ceU suspensions prepared from spleen or pooled peripheral LN cells were treated by flow cytometry (FACS| Becton Dickinson & Co., Mountain View, CA) using a panel of antibodies including Thy-l.2, K, CD4, CD8, CD11b, CD32, CD43, and CD45R (B220). FACS | and histopathologic criteria used to stage the progression of MAIDS have been described in detail (7, 27) . For proliferative responses, cultured spleen cells were stimulated with Con A (5 #g/ml), Con A plus PMA (10 ng/ml), PMA plus ionomycin, or LPS (20/~g/ml). Proliferative responses were measured after pulsing with [3H]thymidine at 72 h. Supernatants were harvested at 24 h for measurements of IL-2 and at 48 h for IFN-% I1-2 was measured using the I1-2-dependent cell line CTLL or by ELISA, and IFN-~/by twosite ELISAs performed as previously described (28) . Serum IgG and IgM levels were determined by ELISA as described (29) .
Semiquantitative Reverse Transc@tase (RT)-PCR. The sequence of hypoxanthine phosphoribosyltransferase (HPRT) primers and probes and techniques used for PCR analysis of viral gene expression were published elsewhere (30) . For detection of BM5def and ecotropic virus mRNAs, the following primers and probe were used respectively: 5'-CCTTTTCCTTTATCGACACT-3', 5'-ACC-A~GGAATACC'IEG-3', and 5'-CTCIGCCAAAGGGAC-CAGTT-3'; 5'-GGCCTAGAATATCGGGCTC-3', 5'-TGTAGT-CCTGGTCGTGGATG-Y, and 5'-CCCTGCTGTTCAGGAAGC-A-Y. Briefly, total RNA was isolated from spleen or LN samples frozen in RNAzol, followed by extraction with chloroform and isopropanol. 1/zg of RNA was transcribed using MMLV-H-reverse transcriptase (Promega Corp., Madison, WI). After this reaction, the cDNA-containing solution was used for specific sequence amplification using 1 U Taq DNA polymerase and 40 ng each of sense and antisense primers. The number of cycles was chosen experimentally for each gene product: ecotropic helper, 30 cycles and LP-BM5def, 23 cycles. As control for the RT-PCR, HPRT (23 cycles) was transcribed and amphfied for all samples. Finally, PCR products were separated on 1% agarose gels and analyzed by Southern blot hybridization with fluorescein-labeled probes using an ECL-Y oligolabeling and detection system and Hyperfilm-ECL (Amersham International, Little Chalfort, UK).
Results and Discussion
Two protocols were used to evaluate the effects of IL-12 during MAIDS. To determine if IL-12 would inhibit induction of disease, B6 mice were treated with rlL-12 for 4 or 8 wk beginning within a day after infection with LP-BM5 MuLV. At 4 and 8 wk after infection, mice were examined for progression of MAIDS. To evaluate if IL-12 would be useful in treatment of mice with established disease, cytokine injections were initiated 4 wk post virus inoculation and were continued for 4 wk before testing.
Chronic treatment with rlL-12 by either protocol had profound effects on the development of MAIDS. As shown in Table 1 , rlL-12-treated mice had significantly reduced spleen and cervical LN weights and marked reductions in the severity of histopathologic changes in lymphoid and nonlymphoid * Treatment with rlL-12 reduces development of splenomegaly and lymphadenopathy in mice infected with LP-BM5 MuLV. B6 mice were inoculated intraperitoneaUy at 6 wk of age with 0.1 ml of virus stocks prepared as previously described (7). Numbers indicate the mean + 1 SE for data from four individual mice per group. * For histopathologic (PATH) and flow cytometry (FACS) determinations of MAIDS progression, N indicates indistinguishable from normal; R indicates reactive to infection but with insui~cient changes to be diagnostic of MAIDS; and 1, 2, and 3 are indicative of changes clearly diagnostic of MAIDS and of increasing severity. The criteria used for determining these stages of disease were detailed previously (6, 7). S Difference statisically significant (Schette test), p <0.05 when compared with results obtained from mice infected with LP-BM5 MuLV and treated with rlL-12.
II Treatment with rlL-12 alone induces transient increases in spleen weight, mainly due to an expansion of the red pulp, which can be observed in animals killed shortly after cessation of immunotherapy. Staging of MAIDS by histopathology and FACS | analysis demonstrated that these increases in spleen weight could not be attributed to advanced MAIDS as seen in spleens of infected untreated mice in the same protocol.
tissues described previously for LP-BM5 virus-infected mice (7; Table 1 ). Spleens and LN of mice with MAIDS normally contain greatly increased numbers of immunoblasts, plasmablasts, and plasma cells (7) . These populations are readily identified by their reduced expression of Ig r and CD45(B220) and increased expression of CD43, an antigen absent on resting B cells but expressed on presecretory and secretory B lineage cells (Fig. 1 ). Both treatment protocols significantly reduced the proportions and total numbers of B cell blasts and plasma cells in spleen (Fig. 1 A) and LN ( Fig. 1 B) . IL-12 treatment also reduced the proportions and total numbers of the unusual subset of CD4 + Thy-1-TCR-ct/3 + T cells that accumulates progressively in spleen and LN of mice with MAIDS (27; Fig. 1 ). Consistent with the reductions in cells with Ig-secreting phenotypes described above, IL-12-treated mice exhibited significantly reduced levels of serum IgG and IgM (Fig. 2) . The concentrations of both Ig dasses did not differ significantly from those of IL-12-treated uninfected mice (not shown) or normal controls (Fig. 2) .
Treatment with rlL-12 also prevented virus-induced abnormalities in T cell proliferative responses and cytokine secretion. While spleen cells from mice with MAIDS were greatly impaired in their ability to proliferate or to produce IL-2 in response to various stimuli, the responses of cells from treated mice did not differ significantly from those of normal, unin-
2201
Gazzinelli et al.
fected mice or of uninfected mice treated with rlL-12 ( Fig. 3) . The ability of rlL-12 treatment to prevent immune dysfunction in virus-infected mice also extended to the expression of IFN-'y protein following stimulation of spleen cells with mitogen (Table 2 ). In agreement with earlier studies (12; Giese, N., unpublished observations), production of IFN-'y by mitogen-stimulated spleen cells was progressively impaired following infection with LP-BM5 MuLV, whereas Type 2 cytokine (IL-4 and IL-10) synthesis was increased (Table  3 ). In contrast, spleen cells from either uninfected or infected mice treated with rlL-12 for the first 4 wk post inoculation produced cytokine levels comparable to those generated by cells from normal, uninfected animals (Tables 2 and 3) .
We conclude that in vivo treatment of mice with rlL-12 significantly inhibited induction of MAIDS when used immediately after infection and was effective in reversing many manifestations of this syndrome when used to treat established disease. The blocking effects on progression of MAIDS were found to persist through 4 wk (Tables 1 and 2 ) and up to 10 wk (not shown) after cessation of treatment. Furthermore, marked reductions in lymphoproliferation and prolonged survival have been observed in mice treated as late as 8 wk post infection (data not shown).
In all infectious disease systems examined previously, protective effects of IL-12 have been dependent on IFN-3~ (17, 31, 32) . We examined the contribution of IFN-'y expression (Fig. 4) or improvement in FACS ® profiles (data not shown) as a result of treatment. In addition, serum IgG levels of the knockout mice infected with LP-BM5 and treated with IL-12 were the same as those mice infected but untreated (Fig. 4) . In the second system, IL-12-inoculated mice were treated simultaneously with high levels of neutralizing mAb to IFN-% Treatment with the mAb completely blocked the ability of IL-12 to inhibit lymphoproliferation (Table 4 ). In addition, there were no differences in the histopathologic changes or abnormalities of cell surface antigen expression exhibited by infected, untreated mice and infected mice treated simultaneously with rlL-12 and anti-IFN-y (data not shown). The combined results from these systems demonstrated that the therapeutic effects of rlL-12 were highly dependent on expression of IFN-% To determine if treatment with rlL-12 altered expression of the MuLV involved in MAIDS, splenic m R N A s were examined by R T -P C R techniques for transcripts from both ecotropic helper and BM5def viruses (Fig. 5) . Studies of spleens from infected mice treated with rlL-12 for 4 w k post infection and studied at 4 w k after virus inoculation revealed reangle light scatter and exclusion of propidium iodide. The numbers in the quadrants of the contour plots generated from the two-color analyses indicate the percent of cells bearing each of the phenotypes. Similar results were obtained in three separate experiments in studies of both spleen and LN cells. duced expression of BMSdef as well as ecotropic virus in the spleens of treated mice (Fig. 5 A, experiment I ). Similar effects of treatment were seen with mRNA from spleens of animals treated for 4 or 8 wk post infection and examined at 9 wk after virus inoculation (Fig. 5 A, experiment II) . To quantitate the effects of IL-12 treatment on expression of the helper and defective virus, we determined the ratio of BMSdef or ecotropic helper virus mRNAs to HPRT transcripts in each of the samples from 14 untreated and 22 treated mice (Fig.  5 B) . Transcripts of the defective virus were present in all preparations from treated animals but were clearly reduced (10-fold difference in means) below the levels of untreated animals. Reduced expression of BMSdef could not be attributed solely to inhibition of helper virus replication by IL-12, as the levels of ecotropic virus mRNA for II~12-treated mice were reduced about threefold compared with levels for un- * Treatment with rlL-12 restores inducibility of IFN-3'. The groups of mice presented received the cytokine treatment from week 0 to 4 on the same schedule and dose decribed in Table 1 . Groups of uninfected B6 mice treated with rlL-12 were used as controls. Numbers indicate the mean for four mice per group. Spleen cells were cultured in media alone or Con A (5 #g/ml) as detailed elsewhere (12) . Supernatants were harvested at 48 h for assay of IFN-"/. Cytokine measurements were performed by two-site ELISA tests as previously described (12, 28 treated, infected mice (Fig. 5 B) . Further studies of the effects of Ib12 treatment on expression of ecotropic MuLV by infectious center tests showed that the frequencies of virusproducing spleen cells were generally comparable for Ib 12-treated or untreated, infected mice (data not shown).
The basis for the dissociation between expression of BMSdef and ecotropic helper virus transcripts in infected mice treated with IL-12 is unclear. Studies orb cell lymphomas that contain and express BM5def showed that treatment with IL-12 in vitro did not affect cell viability or proliferative rate and did not reduce the levels of defective virus mRNA (data not shown), suggesting that the cytokine did not act directly on B cells by eliminating targets for BMSdef expression or altering the rate of virus transcription. It is known, however, that BMSdef is expressed at highest levels in B lymphocytes, whereas the helper virus might be less specific in terms of its target cells. Therefore, an inhibitory effect of IL-12 treatment on B lymphocyte activation and expansion could explain this discrepancy. We examined these possibilities in studies of mice tested immediately after completion of treatment with IL-12. It should be noted, first, that splenomegaly, due primarily to expansion of the red pulp and congestion, develops in mice treated with IL-12, with the increases being more prominent in infected animals (Table 5 and data not shown). These IL-12-induced changes resolve rapidly after cessation of treatment of both infected and uninfected mice. By 8 wk post infection, the beneficial effects of IL-12 in preventing development of splenomegaly due to virus were again evident (Table 5) .
Further studies showed that the frequencies of B cells in spleens of mice treated with IL-12 were reduced, particularly in tissues of infected mice ( Table 5 ). The increases in spleen size associated with IL-12 treatment did not compensate for these reductions, as lymphocyte recovery from the congested spleens was reduced (data not shown). In contrast, LN from IL-12-treated mice had twice the normal frequency of B cells for both infected and uninfected mice, indicating that IL-12 altered the trafficking of B cells (Giese, N., unpublished observations). The demonstration of disproportionately reduced proliferative responses to LPS by spleen cells from infected, IL-12-treated mice (Table 5) indicated that treatment altered not only the total numbers but the biologic responses of B cells.
Treatment with rlL-12 dramatically changed the cytokine profile of infected mice, which in untreated animals was characterized by a dominance of Type 2 cytokines (Tables 2 and  3 ). During IL-12 treatment, we observed greatly enhanced * The results presented in this table were obtained from animals of the same experimental group described in Table 1 . Numbers indicate the mean for four mice per group. Spleen cells were cultured in media alone or with Con A (5 gg/ml) plus PMA (10 ng/ml) as detailed elsewhere (12) . Supernatants were harvested at 24 h and 72 h for assay, respectively, for IL-4 and IL-10. Cytokine measurements were performed as previously described (12, 28) . * Difference statistically significant (Schette test, p <0.05) when compared with results obtained from infected or control mice treated with rlL-12.
expression of IFN-'y accompanied by decreased levels of IL-4 and IL-10. It is noteworthy that spleen cells from infected mice treated with IL-12 not only gained the ability to produce high levels of IFN-3' upon Con A stimulation but pro- Spleens and sera were collected at 9-10 wk post infection. Serum IgG levels were determined by ELISA as previously described (29) . The differences in the Ig levels and spleen weights were significantly different (p <0.05) for treated and untreated wild-type infected animals.
duced remarkable amounts of IFN-y spontaneously-a phenomenon that has been seen after infection of resistant strains of mice including A/J, BALB/c, and 129 (Giese, N., and R. Morawetz, unpublished observations). After cessation of cytokine therapy, spontaneous production of IFN-'y gradually decreased with time followed by a period of"remission" in development of MAIDS lasting up to 10 wk. Subsequently, as noted above, the mice developed the full spectrum of features characteristic of MAIDS including progressive lymphoproliferation, immunodeficiency, and increased expression of Type 2 cytokines. Based on the findings presented here as well as on studies performed with the IL-4 knockout B6 mice (14) , we believe that induction of a vigorous Type 1 response featuring highlevel expression of IFN-'y and NK cell activation, rather than inhibition of Type 2 cytokine synthesis, is the basis of IL-12 therapeutic effects during MAIDS. Thus, treatment with IL-12 would result in strong cell-mediated immunity, control of virus replication, and delay of pathologic manifestations characteristic of MAIDS rather than causing a permanent switch from Th2 to Thl cell activation and resistance to disease. It is likely that in vivo treatment with IL-12 would affect B cell activation and proliferation by inducing high levels of IFN-'y (33) and/or restricting proliferation of Th2 lymphocytes (34) and, secondarily, the production of Type 2 cytokines that are essential for B lymphocyte expansion (35, 36) . Since B cells are the primary targets for infection and expression by BMSdef, control of their proliferation would restrict BM5def virus expression, thus limiting the drive for CD4 T cell polyclonal activation and progression of MAIDS. In addition, by acting directly on NK cells (15) and CD8 + lymphocytes (19) , as well as stimulating Thl expansion and limiting Th2 development (20) (21) (22) (23) , IL-12 could exert other beneficial effects favoring development of effective ceU-mediated functions against BM5def. A mechanism involving CD8 § lymphocytes dearly contributes to virus clearance in MAIDSresistant A/J mice (37) . Recent studies show that treatment with rlL-12 can also enhance immunity to other viral infections such as lymphocytic choriomeningitis virus (38) . It is well documented that the course of HIV infection has certain features, other than immunodeficiency, that parallel observations made in MAIDS. These include chronic B cell activation, hypergammaglobulinemia, and persistent generalized lymphadenopathy due to B cell proliferation (39, 40) . In addition, different studies have demonstrated that a functional defect in the synthesis of Type 1 cytokines by T lymphocytes may occur during the later stages of HIV infection preceding the decrease in CD4 + lymphocyte counts (41, 42) . In conjunction with recent studies showing impaired IL-12 production in HIV-infected patients (43) , IL-12 stimulation of IL-2 and IFN-y synthesis by peripheral blood cells from HIV-infected individuals (44, 45) , enhanced NK cytotoxicity (44) , and enhanced HIV-specific responses of PBC from HIV + individuals (46) , the results presented here support the concept that IL-12 may be useful in the treatment of retrovirus-induced immunodeficiencies.
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